abstract |
The use of a drug selected from thyrotropin-releasing hormone (HRT), HRT analogues, pharmaceutically acceptable salts, hydrates and prodrugs of HRT and HRT analogs in the manufacture of a drug for the treatment or prevention of idiopathic fatigue related to cancer in a human patient suffering from a neoplastic disorder. |